Déjà Vu: PhRMA, IPA At Loggerheads Again Over India’s IP Laws
This article was originally published in PharmAsia News
Executive Summary
Should innovation be respected by strong patent protection or should flexibilities to break patents take precedence to ensure affordable medicines? PhRMA and IPA squared off on these questions and others during a recent USITC hearing.